AC
AI Cancer Cure

Evidence Atlas, updating nightly

Explore

Latest literature

Cancer research papers

Nightly index of recent papers from PubMed, bioRxiv, and medRxiv. Filters are designed for both researcher precision and patient-friendly navigation.

Learn how we rate papers in our methodology.

Starting focus

Cholangiocarcinoma

We’re indexing all cancers but highlighting cholangiocarcinoma while the evidence atlas expands.

View cholangiocarcinoma papers
3 papersSorted by most recent
Peer-reviewedImpact 71

Topics

Treatment, Side effects / Toxicity

Modality

Targeted therapy, Imaging

Study type

Not listed

Abstract

Synthetic lethality has proven to be a tactical paradigm to design synergistic anticancer drug combinations. In this context, we leveraged BRCA2 and PARP as a synthetic lethal target pair to consolidate the use of small molecule inhibitors of RAD51-BRCA2 protein-protein interaction as inducers of…

Authors

Giovanni Ferrandi, Greta Bagnolini, Laura Poppi, Mirco Masi +10

AI-generated summary

Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series. reports: Synthetic lethality has proven to be a tactical paradigm to design synergistic anticancer drug combinations. In this context, we leveraged BRCA2 and PARP as a synthetic lethal target pair to consolidate the use of small molecule inhibitors of RAD51-BRCA2 protein-protein interaction as inducers of the BRCAness phenotype that sensitizes BRCA2 -functional cancer cells to PARP inhibitors. Starting from compound 1 , a phenyl furan-carboxyquinoline, we developed a series of analogues, leading to derivative 19 .

This summary may be inaccurate. Verify with the primary paper.

Primary source: PubMed.

PreprintImpact 42

Topics

Treatment, Diagnosis, Screening / Early detection, Prevention / Risk

Modality

Surgery, Imaging

Study type

Review / Meta-analysis

Abstract

BackgroundWith widening therapeutic indications, germline genetic testing is offered to an increasing proportion of patients with breast cancer (BC) via mainstream oncology services. However, the gene set tested varies widely from just BRCA1/BRCA2 through to pan-cancer panels of near 100 genes. If a germline…

Authors

Turnbull, C., Achatz, M. I., Balmana, J., Castro, E. +14

AI-generated summary

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendations reports: BackgroundWith widening therapeutic indications, germline genetic testing is offered to an increasing proportion of patients with breast cancer (BC) via mainstream oncology services. However, the gene set tested varies widely from just BRCA1/BRCA2 through to pan-cancer panels of near 100 genes. If a germline pathogenic variant (GPV) is detected, the BC proband and other family GPV-carriers may be offered interventions such as risk-reducing surgery and decades of intensive surveillance for the various cancers linked to that gene. This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: medRxiv (not peer reviewed).

Peer-reviewedImpact 53

Topics

Diagnosis, Screening / Early detection, Outcomes / Survival, Prevention / Risk, Epidemiology

Modality

Imaging

Study type

Observational

Abstract

There is little evidence on breast cancer (BC) diagnosed in women with a high genetic risk, before and after their inclusion in a long-term risk management program based on genetic risk assessment. We analyzed clinical outcomes in women enrolled in the Phare Grand Ouest…

Authors

Ke Zhou, Caroline Abadie, Louise Crivelli, Euriell Fortin +2

AI-generated summary

From genetic risk to early detection - clinical outcomes of a person-centered screening program for women with a high genetic risk of breast cancer. reports: There is little evidence on breast cancer (BC) diagnosed in women with a high genetic risk, before and after their inclusion in a long-term risk management program based on genetic risk assessment. We analyzed clinical outcomes in women enrolled in the Phare Grand Ouest (PGO) program. The PGO includes carriers of the BRCA1 and BRCA2 pathogenic variants (PV) and women at high risk without BRCA PV , enrolled in eight cancer genetics units.

This summary may be inaccurate. Verify with the primary paper.

Primary source: PubMed.